Market cap
$1,869 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
3
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-43 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-11.8
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.7
-
Face value
--
-
Shares outstanding
126,812,000
10 Years Aggregate
CFO
$-210.50 Mln
EBITDA
$-219.26 Mln
Net Profit
$-214.63 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
BELLUS Health Inc (BLU)
| 79.3 | 1.0 | 128.2 | 46.8 | 7.0 | 58.1 | 33.3 |
|
BSE Sensex*
| -12.1 | -3.8 | -4.1 | -9.7 | 5.9 | 7.5 | 10.8 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
BELLUS Health Inc (BLU)
| 2.1 | 163.1 | -59.7 | 176.0 | 154.0 | 46.2 | -72.2 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout BELLUS Health Inc (BLU)
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the... P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc. Read more
-
Pres, CEO & Director
Mr. Roberto Francesco Bellini
-
Pres, CEO & Director
Mr. Roberto Francesco Bellini
-
Headquarters
Laval, QC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for BELLUS Health Inc (BLU)
What is the current share price of BELLUS Health Inc (BLU) Today?
The share price of BELLUS Health Inc (BLU) is $14.74 (NASDAQ) as of 06-Jul-2023 09:30 EDT. BELLUS Health Inc (BLU) has given a return of 7.04% in the last 3 years.
What is the current PB & PE ratio of BELLUS Health Inc (BLU)?
Since, TTM earnings of BELLUS Health Inc (BLU) is negative, P/E ratio is not available.
The P/B ratio of BELLUS Health Inc (BLU) is 3.02 times as on 06-Jul-2023, a 2 discount to its peers’ median range of 3.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-12.43
|
2.42
|
|
2021
|
-8.93
|
2.18
|
|
2020
|
-5.68
|
1.23
|
|
2019
|
-13.53
|
4.05
|
|
2018
|
-4.29
|
0.70
|
What is the 52 Week High and Low of BELLUS Health Inc (BLU)?
The 52-week high and low of BELLUS Health Inc (BLU) are Rs -- and Rs -- as of 10-Jun-2026.
What is the market cap of BELLUS Health Inc (BLU)?
BELLUS Health Inc (BLU) has a market capitalisation of $ 1,869 Mln as on 06-Jul-2023. As per SEBI classification, it is a company.
Should I invest in BELLUS Health Inc (BLU)?
Before investing in BELLUS Health Inc (BLU), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.